[{"source": "https://www.youtube.com/feeds/videos.xml?channel_id=UCF9IOB2TExg3QIBupFtBDxg", "title": "Indian variant now in US", "description": "India\nhttps://www.aljazeera.com/news/2021/5/2/vote-count-in-five-indian-states-underway-amid-raging-pandemic\n\nCases, + 392,488 = 19,500,000\n\nDeaths, + 3,689 = 215,542\n\nNevada, 7 cases of India variant, B.1.617\n\nhttps://www.reviewjournal.com/local/local-nevada/7-cases-of-indias-double-mutant-coronavirus-identified-in-nevada-2343233/\n\nSix in Washoe County\n\nOne in Churchill County\n\nHeather Kerwin, epidemiology program manager\n\nWashoe County residents, did not appear to have travelled\n\nCenters for Disease Control and Prevention, B.1.617 not listed as VOI or VOC\n\nCambodia\n\nPopulation, 15 million\n\nWorst outbreak so far\n\nAll linked to B.1.1.7\n\nBan in inter-district travel\n\nMandatory masks\n\nNight curfew \n\nEnforced lockdowns since 5th April\n\nRed zones\n\nAll markets in Phnom Penh closed\n\nFood often not delivered by government\n\nFirst dose, 1.3 million\n\nMostly Sinopharm with some Sinovac and COVAX AZ\n\nUS\n\nCases\n\nhttps://covid.cdc.gov/covid-data-tracker/#trends_dailytrendscases\n\nVaccinations\n\nhttps://covid.cdc.gov/covid-data-tracker/#vaccinations\n\nUK\n\nhttps://coronavirus.data.gov.uk\n\nhttps://covid.joinzoe.com/data\n\nLongitudinal analysis shows durable and broad immune memory after SARS-CoV-2 infection with persisting antibody responses and memory B and T cells\n\nhttps://www.medrxiv.org/content/10.1101/2021.04.19.21255739v1\n\nSeattle and Atlanta\n\nn = 254 COVID-19 patients\n\n55% female, 45% male\n\nAges, 18-82 \n\nLongitudinally from early infection and for eight months\nfound a predominant broad-based immune memory response\n\nSpike binding and neutralizing antibodies exhibited a bi-phasic decay\n\nWith an extended half-life of more than 200 days\n\nSuggesting the generation of longer-lived plasma cells\n\nSustained IgG+ memory B cell response\n\nBodes well for a rapid antibody response upon virus re-exposure\n\nVirus-specific CD4+ and CD8+ T cells were generated and maintained\nEstimated half-life of 200 days\n\nCD4+ T (helpers) cell response equally targeted several SARS-CoV-2 proteins\n\nCD8+ T (cytotoxic) cell response preferentially targeted the nucleoprotein\n\nImportance of including the nucleoprotein as a potential vaccine antigen\n\nFollow up for next 3 years", "link": "https://www.youtube.com/watch?v=OIIylMJV7wQ", "date_published": "2021-05-03 00:00:00+00:00", "persistent": false, "user": null, "language": "en-US"}, {"source": "https://www.youtube.com/feeds/videos.xml?channel_id=UCF9IOB2TExg3QIBupFtBDxg", "title": "Virus in Italy, September 2019", "description": "Unexpected detection of SARS-CoV-2 antibodies in the prepandemic period in Italy\n\nhttps://pubmed.ncbi.nlm.nih.gov/33176598/\n\nhttps://journals.sagepub.com/doi/10.1177/0300891620974755?url_ver=Z39.88-2003&rfr_id=ori%3Arid%3Acrossref.org&rfr_dat=cr_pub++0pubmed&\n\nPresence of SARS-CoV-2 receptor-binding domain (RBD)-specific antibodies\n\nBlood samples of 959 asymptomatic individuals enrolled in a prospective lung cancer screening trial\n\nItaly's first two cases of COVID-19 disease\n\nJanuary 30, 2020, two tourists from China in Rome\n\nFirst laboratory-confirmed Italian COVID-19 case, Lombardy on February 20, 2020,\n\nSeptember 2019 to March 2020\n\nSARS-CoV-2 RBD-specific antibodies were detected in 111 of 959 (11.6%) individuals\n\nIgM and some IgG\n\nSeptember 2019,  23/111\n\nOctober,    27/111\n\nNovember,   26/111\n\nDecember,   11/111\n\nJanuary,    3/111\n\nFebruary,   21/111\n\nUnexpected very early circulation of SARS-CoV-2 among asymptomatic individuals in Italy\n\nAt least one SARS-CoV-2\u2013positive patient was detected in 13 regions\n\nIgM antibodies were detected in 97 (10.1%) patients\n\nIgG antibodies were found in 16 (1.7%)\n\nAll the patients were asymptomatic at the time of\nblood sample collection.\n\nFirst IgM detected 3rd September\n\n\nInfection more widespread than believed\n\nTherefore an overestimation of the mortality rate\n\nSince November to December 2019\n\nMany general practitioners began reporting severe respiratory symptoms in elderly\nand frail people\n\nAtypical bilateral bronchitis\n\n(? organising pneumonia)\n\nAttributed to aggressive forms of seasonal influenza.\n\nNational Library of Medicine\n\nhttps://pubmed.ncbi.nlm.nih.gov/32371096/\n\nParis, December 2019\n\nPatient hospitalized for hemoptysis\n\nStored nasopharyngeal swab confirmed the diagnosis of\n\nSARS-CoV-2 infection.\n\nHarvard Library, Since autumn 2019\n\nhttps://dash.harvard.edu/handle/1/42669767\n\nIncrease of hospital traffic in the Wuhan region\n\nSatellite imagery\n\nCOVID-19 symptoms\u2013related queries in search engines\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\nAntibody Persistence through 6 Months after the Second Dose of mRNA-1273 Vaccine for Covid-19\n\nhttps://www.nejm.org/doi/full/10.1056/NEJMc2103916?emp=marcom&utm_source=nejmlist&utm_medium=email&utm_campaign=aomev2&utm_content=version-c\n\nModerna mRNA-1273 severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) \n\nEfficacy 94% in phase 3 trials\n\nDurability of protection, 180 days after 2nd dose\n\nAntibody activity remained high in all age groups at day 209\n\nResults are consistent with convalescent patients with Covid-19 through 8 months after symptom onset \n\nSupport the use of this vaccine in addressing the Covid-19 pandemic.", "link": "https://www.youtube.com/watch?v=i195K2vYfnY", "date_published": "2021-05-02 00:00:00+00:00", "persistent": false, "user": null, "language": "en-US"}]